Soleno Therapeutics Inc (SLNO) Insider Trading

Last 12 months

Insiders sold $429k and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Commercial Officer Meredith Manning sold $229k on Mar 27, 10% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2022.

Net open-market

−$429k

0 buys · 2 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

Mar 2022

Mar 31, 2022

Get an email when SLNO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Mar 27	Michael F. Huang Sr. VP of Clinical Development	SoldNo plan 3 parts	6,582	$30.44 average	$200k	14%	Form 4
Mar 27	Meredith Manning Chief Commercial Officer	SoldNo plan 3 parts	7,522	$30.44 average	$229k	10%	Form 4
Jul 1, 2025	Patricia C Hirano SEE REMARKS	Sold10b5-1 plan	3,830	$82.76	$317k	22%	Form 4
Jun 24, 2025	Patricia C Hirano SEE REMARKS	Sold10b5-1 plan	266	$84.25	$22k	1.5%	Form 4
Apr 1, 2025	Patricia C Hirano SEE REMARKS	Sold10b5-1 plan	3,782	$70.11	$265k	12%	Form 4
Mar 28, 2025	Matthew Pauls Director	SoldNo plan	5,937	$71.55	$425k	48%	Form 4
Mar 27, 2025 – Mar 28, 2025	Patricia C Hirano SEE REMARKS	Sold10b5-1 plan 16 parts	156,315	$68.51 average	$10.7M	84%	Form 4
Mar 26, 2025 – Mar 28, 2025	Vivo Opportunity Fund Holdings, L.p. Large holder	SoldNo plan 3 parts	1,833,557	$67.87 average	$124M	29%	Form 4
Mar 27, 2025	Kristen Yen SEE REMARKS	SoldNo plan 10 parts	95,500	$66.77 average	$6.38M	77%	Form 4
Mar 27, 2025	Meredith Manning Chief Commercial Officer	SoldNo plan 9 parts	45,249	$67.28 average	$3.04M	50%	Form 4
Mar 27, 2025	James H Mackaness CHIEF FINANCIAL OFFICER	SoldNo plan 11 parts	90,622	$69.45 average	$6.29M	46%	Form 4
Mar 27, 2025	Michael F. Huang Sr. VP of Clinical Development	SoldNo plan 9 parts	14,583	$69.51 average	$1.01M	28%	Form 4
Mar 27, 2025	Bhatnagar Anish CHIEF EXECUTIVE OFFICER	SoldNo plan 12 parts	699,095	$67.62 average	$47.3M	55%	Form 4
Jan 2, 2025 – Jan 3, 2025	Kristen Yen SEE REMARKS	SoldNo plan 3 parts	4,860	$45.78 average	$223k	6.0%	Form 4
Jan 2, 2025 – Jan 3, 2025	James H Mackaness CHIEF FINANCIAL OFFICER	SoldNo plan 3 parts	7,874	$45.78 average	$360k	6.6%	Form 4
Jan 2, 2025 – Jan 3, 2025	Patricia C Hirano SEE REMARKS	SoldNo plan 3 parts	3,030	$45.78 average	$139k	2.8%	Form 4
Jan 2, 2025 – Jan 3, 2025	Bhatnagar Anish CHIEF EXECUTIVE OFFICER	SoldNo plan 3 parts	21,091	$45.78 average	$966k	2.9%	Form 4

Mar 27No plan
Michael F. Huang
Sr. VP of Clinical Development · sold 6,582 at avg $30.44
$200k
14% of stake
Mar 27No plan
Meredith Manning
Chief Commercial Officer · sold 7,522 at avg $30.44
$229k
10% of stake
Jul 1, 202510b5-1 plan
Patricia C Hirano
SEE REMARKS · sold 3,830 at $82.76
$317k
22% of stake
Jun 24, 202510b5-1 plan
Patricia C Hirano
SEE REMARKS · sold 266 at $84.25
$22k
1.5% of stake
Apr 1, 202510b5-1 plan
Patricia C Hirano
SEE REMARKS · sold 3,782 at $70.11
$265k
12% of stake
Mar 28, 2025No plan
Matthew Pauls
Director · sold 5,937 at $71.55
$425k
48% of stake
Mar 27, 2025 – Mar 28, 202510b5-1 plan
Patricia C Hirano
SEE REMARKS · sold 156,315 at avg $68.51
$10.7M
84% of stake
Mar 26, 2025 – Mar 28, 2025No plan
Vivo Opportunity Fund Holdings, L.p.
Large holder · sold 1,833,557 at avg $67.87
$124M
29% of stake
Mar 27, 2025No plan
Kristen Yen
SEE REMARKS · sold 95,500 at avg $66.77
$6.38M
77% of stake
Mar 27, 2025No plan
Meredith Manning
Chief Commercial Officer · sold 45,249 at avg $67.28
$3.04M
50% of stake
Mar 27, 2025No plan
James H Mackaness
CHIEF FINANCIAL OFFICER · sold 90,622 at avg $69.45
$6.29M
46% of stake
Mar 27, 2025No plan
Michael F. Huang
Sr. VP of Clinical Development · sold 14,583 at avg $69.51
$1.01M
28% of stake
Mar 27, 2025No plan
Bhatnagar Anish
CHIEF EXECUTIVE OFFICER · sold 699,095 at avg $67.62
$47.3M
55% of stake
Jan 2, 2025 – Jan 3, 2025No plan
Kristen Yen
SEE REMARKS · sold 4,860 at avg $45.78
$223k
6.0% of stake
Jan 2, 2025 – Jan 3, 2025No plan
James H Mackaness
CHIEF FINANCIAL OFFICER · sold 7,874 at avg $45.78
$360k
6.6% of stake
Jan 2, 2025 – Jan 3, 2025No plan
Patricia C Hirano
SEE REMARKS · sold 3,030 at avg $45.78
$139k
2.8% of stake
Jan 2, 2025 – Jan 3, 2025No plan
Bhatnagar Anish
CHIEF EXECUTIVE OFFICER · sold 21,091 at avg $45.78
$966k
2.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SLNO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

URGNUrogen Pharma Ltd.

CYRXCryoport Inc.

AMRNAmarin Corp PLC\Uk

MGNXMacrogenics Inc.

LFVNLifeVantage Corporation

ABUSArbutus Biopharma Corporation

MRVIMaravai Lifesciences Holdings Inc.

VNDAVanda Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in SLNO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SLNO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.